Go to the Globe and Mail homepage

Jump to main navigationJump to main content


The wrinkle in Valeant’s pursuit of Allergan Add to ...

Subscribers Only

The pursuit of Allergan Inc. is taking on a frantic air.

Perhaps that’s because Valeant Pharmaceuticals International Inc. sees huge untapped value in the Botox maker. More likely, though, it’s because the strategy that has turned the Canadian drug peddler into a stock market superstar is reaching its natural limit.

Report Typo/Error

Follow on Twitter: @IanMcGugan

Next story




Most popular videos »

More from The Globe and Mail

Most popular